WO2018043733A1 - Procédé et kit de détection de micro-organismes pathogènes - Google Patents

Procédé et kit de détection de micro-organismes pathogènes Download PDF

Info

Publication number
WO2018043733A1
WO2018043733A1 PCT/JP2017/031689 JP2017031689W WO2018043733A1 WO 2018043733 A1 WO2018043733 A1 WO 2018043733A1 JP 2017031689 W JP2017031689 W JP 2017031689W WO 2018043733 A1 WO2018043733 A1 WO 2018043733A1
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
virus
pathogenic microorganism
reaction product
hydrophilic solvent
Prior art date
Application number
PCT/JP2017/031689
Other languages
English (en)
Japanese (ja)
Inventor
博行 野地
和仁 田端
Original Assignee
国立研究開発法人科学技術振興機構
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2017099579A external-priority patent/JP7016136B2/ja
Application filed by 国立研究開発法人科学技術振興機構 filed Critical 国立研究開発法人科学技術振興機構
Priority to US16/329,829 priority Critical patent/US11008603B2/en
Priority to EP17846736.1A priority patent/EP3508586A4/fr
Priority to BR112019004272A priority patent/BR112019004272A2/pt
Priority to CN201780054148.5A priority patent/CN109689882A/zh
Publication of WO2018043733A1 publication Critical patent/WO2018043733A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/20—Coumarin derivatives
    • C12Q2334/22—4-Methylumbelliferyl, i.e. beta-methylumbelliferone, 4MU
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a method and kit for detecting pathogenic microorganisms. More specifically, in a minimal volume of hydrophilic solvent coated with a hydrophobic solvent, the pathogenic microorganism is detected by optically detecting the reaction product generated as a result of the reaction by the enzyme on or inside the pathogenic microorganism.
  • the present invention relates to a method for performing detection.
  • Patent Document 1 a simple influenza virus test kit using immunochromatography has been developed (see Patent Document 1). Since the method using immunochromatography can detect influenza virus within minutes to tens of minutes, it is utilized for diagnosis and treatment of infection.
  • Patent Documents 2 and 3 a technique for optically detecting influenza virus based on the reaction between neuraminidase, which is an enzyme of influenza virus, and a chromogenic substrate is known (see Patent Documents 2 and 3).
  • the chromogenic substrate include 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuramic acid: 4MU-NANA, see Patent Document 2), 4-alkoxy A derivative of —N-acetylneuraminic acid or 4,7-dialkoxy-N-acetylneuraminic acid (see Patent Document 3) is used.
  • 4-methylumbelliferone which is a fluorescent substance
  • the neuraminidase enzyme activity value can be calculated based on the amount of 4-methylumbelliferone produced, and the number of influenza virus particles can be quantified based on the enzyme activity value.
  • Non-Patent Document 1 discloses a single-molecule enzyme assay using an array of femtoliter-order droplets in which the droplets are covered with oil and directly accessible from the outside. A method is described.
  • the main object of the present invention is to provide a technique that can be used to detect viruses such as influenza viruses with high sensitivity.
  • the present invention provides the following [1] to [25].
  • [1] A method for detecting the pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism, A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed.
  • An introduction procedure for introducing a hydrophilic solvent containing the biological sample and a substance serving as a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism into a space between the upper layer portion An encapsulation procedure for introducing a hydrophobic solvent into the space, and forming droplets of the hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism and the substance in the container, A detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet, The method, wherein the hydrophilic solvent has a pH value greater than the acid dissociation constant (pKa) of the reaction product.
  • pKa acid dissociation constant
  • the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid), and the reaction product is 4-methylumbelliferone [1] or [2].
  • the pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [1] or [2], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase and RNA-dependent RNA polymerase.
  • the substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine. [1] or [2].
  • a method for diagnosing the presence or absence of infection with a pathogenic microorganism A procedure for separating a biological sample from a subject suspected of being infected; A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed.
  • the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid) and the reaction product is 4-methylumbelliferone, [6] to [8].
  • the pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus Any one of [6] to [8], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase, and RNA-dependent RNA polymerase.
  • the substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine. Any one of [6] to [8].
  • a method for detecting drug sensitivity of a pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed.
  • the hydrophilic solvent has a pH value larger than an acid dissociation constant (pKa) of the reaction product.
  • the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid), the reaction product is 4-methylumbelliferone, and the inhibitor is a neuraminidase inhibitor [12] or [13].
  • a method of screening for anti-pathogenic microbial agents A plurality of accommodating parts capable of accommodating pathogenic microorganisms are opposed to a lower layer part formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface on which the accommodating part is formed in the lower layer part Introducing a hydrophilic solvent containing the pathogenic microorganism, a substance serving as a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism, and a candidate compound into a space between the upper layer portion and the upper layer portion When, An enclosing procedure for introducing a hydrophobic solvent into the space and forming droplets of a hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism, the substance, and the candidate compound in the container.
  • the hydrophilic solvent has a pH value larger than an acid dissociation constant (pKa) of the reaction product.
  • the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid), the reaction product is 4-methylumbelliferone, and a neuraminidase inhibitor is screened as the candidate compound [15] or [16].
  • a kit for detecting the pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism A space between a lower layer portion in which a plurality of accommodating portions capable of accommodating the pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed
  • An array comprising an upper layer portion facing each other, and A substance that is a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism;
  • a kit comprising a hydrophobic solvent.
  • the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid), and the reaction product is 4-methylumbelliferone [18].
  • the pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, Middle East respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [18] The kit according to [18], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase, and RNA-dependent RNA polymerase.
  • the substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine.
  • a method of detecting a reaction product by reacting an enzyme with a substance serving as a substrate for a reaction by the enzyme in a hydrophilic solvent in interface with the hydrophobic solvent The method, wherein the hydrophilic solvent has a pH value greater than the acid dissociation constant (pKa) of the reaction product.
  • the hydrophilic solvent contains a pathogenic microorganism,
  • the enzyme is an enzyme having a substrate cleavage activity present on the surface or inside of the pathogenic microorganism,
  • the substance is a chromogenic substrate;
  • the method according to [22] wherein a reaction product generated by cleavage of the chromogenic substrate by the enzyme is optically detected.
  • the pathogenic microorganism is an influenza virus
  • the enzyme is neuraminidase
  • the chromogenic substrate is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-
  • the pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [23] The method according to [23], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase and RNA-dependent RNA polymerase.
  • the chromogenic substrate is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine.
  • the method of [23] which is one or more of the following.
  • the method of any of [23] to [26], wherein the hydrophilic solvent comprises a biological sample separated from a subject infected with or suspected of being infected with the pathogenic microorganism.
  • pathogenic microorganisms include bacteria and viruses.
  • bacteria include, but are not limited to, coliform bacteria, Vibrio parahaemolyticus, Campylobacter, Enterobacter, and Bacillus bacteria.
  • virus is not particularly limited, but for example, coronavirus, SARS virus, MARS virus, influenza virus, mump virus, measles virus, nipavirus, canine distemper virus, HIV, hepatitis B virus, HTLV, Ebola virus, type C Examples include hepatitis virus, Lassa virus, hantavirus, rabies virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus.
  • the present invention provides a technique that can be used to detect pathogenic microorganisms such as influenza virus with high sensitivity.
  • Pathogenic microorganism detection method The pathogenic microorganism detection method according to the present invention is used to detect pathogenic microorganisms in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism. is there.
  • the pathogenic microorganism detection method according to the present invention includes the following procedures.
  • the biological sample is not particularly limited as long as it is a biological material that can contain pathogenic microorganisms to be detected.
  • biological samples include nasal aspirate, nasal swab, throat swab, tracheal swab, saliva, sputum, blood (including whole blood, serum and plasma), urine, cells and tissues, organ extracts, etc. Is mentioned.
  • the pathogenic microorganism is not particularly limited as long as it has an enzyme on the surface or inside thereof and generates a reaction product that can be detected optically as a result of the reaction by the enzyme. More specifically, the pathogenic microorganism has an enzyme having a substrate-cleaving activity for a chromogenic substrate on the surface or inside thereof, and the reaction product as a chromophore is liberated by the cleavage of the chromogenic substrate by the enzyme. .
  • pathogenic microorganisms have an enzyme on the surface or inside that has an activity of synthesizing a polymer by binding a monomer as a substrate, and a reaction generated as a chromophore with the synthesis of the polymer by the enzyme It may be one that generates a product.
  • enzymes on the surface or inside that has an activity of synthesizing a polymer by binding a monomer as a substrate, and a reaction generated as a chromophore with the synthesis of the polymer by the enzyme It may be one that generates a product. Examples of combinations of pathogenic microorganisms and their enzymes include the following.
  • the lower layer portion 10 is formed by a plurality of accommodating portions 13 capable of accommodating virus particles separated from each other by a side wall 12 having a hydrophobic upper surface. Further, the upper layer portion 20 faces the surface of the lower layer portion 10 where the accommodating portion 13 is formed.
  • a hydrophilic solvent 42 is introduced into the space 30 between the lower layer portion 10 and the upper layer portion 20.
  • the hydrophilic solvent 42 may contain virus 2 derived from a biological sample. Further, the hydrophilic solvent 42 includes a substance 3 (hereinafter referred to as “substrate 3”) which is a substrate for a reaction by an enzyme present on the particle surface (or inside) of the virus 2.
  • substrate 3 a substance 3
  • the hydrophilic solvent 42 can be introduced into the space 30 from a through hole (not shown) formed in at least one of the upper layer part 20 and the lower layer part 10, for example. As shown in the drawing, the hydrophilic solvent 42 introduced into the space 30 flows in a direction parallel to the surface where the lower layer portion 10 and the upper layer portion 20 face each other.
  • the hydrophilic solvent 42 has a pH value larger than the acid dissociation constant (pKa) of the reaction product generated from the substrate 3 (details will be described later).
  • the substrate 3 may be any substrate that generates a reaction product having optical characteristics different from those before the reaction after the reaction with the enzyme, and a substance whose absorbance or optical rotation changes before and after the reaction, or exhibits fluorescence after the reaction. The substance that becomes is used.
  • the substrate 3 will be described in detail later.
  • the hydrophilic solvent 42 may contain a buffer substance necessary for optimizing the reaction between the enzyme and the substrate 3. Furthermore, by setting the buffer substance in the hydrophilic solvent 42 to a predetermined concentration or more, the detection of the reaction product can be made more sensitive in the detection procedure (3) (details will be described later).
  • MES 2-Morpholinoethanesulfonic acid
  • ADA N- (2-Acetamido) iminodiacetic acid
  • PIPES Piperazine-1,4-bis (2- ethanesulfonic acid)
  • ACES N- (2-Acetamido) -2-aminoethanesulfonic acid
  • BES N, N-Bis (2-hydroxyethyl) -2-aminoethanesulfonic acid
  • TES N-Tris (hydroxymethyl) methyl- So-called good buffers such as 2-aminoethanesulfonic acid HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid), Tris (tris (hydroxymethyl) aminomethane), DEA (diethanolamine) and the like can be used.
  • the hydrophilic solvent 42 may contain a surfactant.
  • a surfactant By including a surfactant, the enzyme present in the virus 2 may be exposed on the surface.
  • the surfactant by including the surfactant, the hydrophilic solvent 42 tends to be easily introduced into the space 30 and the accommodating portion 13.
  • the surfactant is not particularly limited.
  • TWEEN 20 (CAS number: 9005-64-5, polyoxyethylene sorbitan monolaurate) and Triton X-100 (CAS number: 9002-93-1, generic name polyethylene glycol mono) -4-octylphenyl ether (n ⁇ 10)) and the like.
  • the concentration of the surfactant added to the first solvent 20 is not particularly limited, but is preferably 0.01 to 1%.
  • an anionic surfactant an anionic surfactant, a cationic surfactant, a nonionic surfactant, a zwitterionic surfactant, a naturally derived surfactant and the like can be widely used.
  • anionic surfactant examples include a carboxylic acid type, a sulfate ester type, a sulfonic acid type, and a phosphate ester type.
  • specific examples include sodium dodecyl sulfate, sodium laurate, sodium ⁇ -sulfo fatty acid methyl ester, sodium dodecyl benzene sulfonate, sodium dodecyl ethoxylate sulfate, etc.
  • sodium dodecyl benzene sulfonate is used. It is preferable to use it.
  • Examples of the cationic surfactant are classified into a quaternary ammonium salt type, an alkylamine type, and a heterocyclic amine type. Specific examples include stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, didecyl dimethyl ammonium chloride, cetyl tripyridinium chloride, dodecyl dimethyl benzyl ammonium chloride, and the like.
  • Nonionic surfactants include, for example, polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene mono fatty acid ester, polyoxyethylene sorbitan mono fatty acid ester, sucrose fatty acid ester, polyglycerin fatty acid ester, alkyl polyglycoside , N-methylalkylglucamide and the like.
  • amphoteric surfactants include lauryldimethylaminoacetic acid betaine, dodecylaminomethyldimethylsulfopropylbetaine, and 3- (tetradecyldimethylaminio) propane-1-sulfonate, but 3-[(3-colamide Propyl) dimethylammonio] -1-propanesulfonate (CHAPS), 3-[(3-colamidopropyl) dimethylammonio] -2-hydroxy-1-propanesulfonate (CHAPSO) and the like are preferably used.
  • lauryldimethylaminoacetic acid betaine dodecylaminomethyldimethylsulfopropylbetaine
  • 3- (tetradecyldimethylaminio) propane-1-sulfonate but 3-[(3-colamide Propyl) dimethylammonio] -1-propanesulfonate (CHAPS), 3-[(3-colamidopropyl) dimethylammoni
  • lecithin and saponin are preferable, and among the compounds referred to as lecithin, specifically, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, etc. preferable.
  • a saponin Kiraya saponin is preferable.
  • the virus 2 and the substrate 3 enter the storage unit 13 by this procedure.
  • the number of viruses 2 entering one container 13 can be 0 or 1 at the maximum.
  • the concentration of the virus 2 is higher in the hydrophilic solvent 42, two or more viruses 2 can be introduced into one container 13.
  • the hydrophobic solvent 43 may be any solvent (immiscible solvent) that is difficult to mix with the hydrophilic solvent 42 used in the introduction procedure (1).
  • the hydrophobic solvent 43 include at least one selected from the group consisting of saturated hydrocarbons, unsaturated hydrocarbons, aromatic hydrocarbons, silicone oils, perfluorocarbons, halogenated solvents, and hydrophobic ionic liquids. A mixture or the like can be preferably used.
  • saturated hydrocarbons include alkanes and cycloalkanes. Examples of alkane include decane and hexadecane. Examples of the unsaturated hydrocarbon include squalene.
  • aromatic hydrocarbons include benzene and toluene.
  • the perfluorocarbon examples include Fluorinert (registered trademark) FC40 (manufactured by SIGMA).
  • the halogen solvent examples include chloroform, methylene chloride, chlorobenzene and the like.
  • the hydrophobic ionic liquid refers to an ionic liquid that does not dissociate at least in water, and examples thereof include 1-Butyl-3-methylimidazolium, Hexafluorophosphate.
  • An ionic liquid refers to a salt that exists as a liquid at room temperature.
  • the hydrophobic solvent 43 may be introduced into the space 30 from a through-hole (not shown) formed in at least one of the upper layer portion 20 and the lower layer portion 10, similarly to the hydrophilic solvent 42. As shown in the drawing, the hydrophobic solvent 43 introduced into the space 30 flows in a direction parallel to the surface where the lower layer portion 10 and the upper layer portion 20 face each other, and the hydrophilic solvent 42 in the space 30 is a hydrophobic solvent. 43 is substituted. As a result, a droplet of the hydrophilic solvent 42 that is covered with the hydrophobic solvent 43 and includes the virus 2 and the substrate 3 is formed in the accommodating portion 13.
  • reaction product 4 is present on or inside the particle of virus 2 (the figure shows the case where enzyme 5 is present on the virus surface).
  • a reaction product 4 is generated.
  • the colored product 4 exhibits optical characteristics different from those of the substrate 3 and exhibits, for example, a shift in absorbance and optical rotation and luminescence (fluorescence).
  • the volume of the container 13 (that is, the volume of the droplet of the hydrophilic solvent 42) is not particularly limited, but is, for example, 10 aL to 100 nL, preferably 1 fL to 1 pL.
  • Virus 2 is an influenza virus (see Table 1), and 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic acid: 4MU-NANA) is used as substrate 3 The case where it is used will be described specifically by way of example.
  • Neuraminidase (enzyme 5) is present on the surface of influenza virus particles.
  • 4MU-NANA substrate 3
  • 4-methylumbelliferone reaction product 4
  • 4-Methylumbelliferone is generated as a fluorescent chromophore represented by the following formula, derived from hydrolysis of 4MU-NANA by neuraminidase.
  • the substrate 3 is not limited to 4MU-NANA, and any conventionally known one can be used as long as it releases a chromophore that can be detected optically by neuraminic acid hydrolysis by neuraminidase.
  • 4MU of the reaction product 4 has a hydroxyl group as shown by the following formula.
  • hydrogen is desorbed from the hydroxyl group of 4 MU to bring 4 MU into a charged state, so that the pH value of the hydrophilic solvent 42 is higher than the acid dissociation constant (pKa) of 7.79 of 4 MU. Set larger.
  • the 4MU contained in the droplet of the hydrophilic solvent 42 coated with the hydrophobic solvent 43 cannot move to the hydrophobic solvent 43 due to its charge, and as a result It accumulates in a high concentration in the droplets of the hydrophilic solvent 42.
  • the pH value of the hydrophilic solvent 42 is smaller than the acid dissociation constant (pKa) of 4 MU, 4 MU has a hydroxyl group, and therefore has no charge or when hydrogen is desorbed from the hydroxyl group. In comparison, the charge is reduced.
  • the 4MU contained in the droplet of the hydrophilic solvent 42 has no electric charge or has a small electric charge, the 4MU easily moves to the hydrophobic solvent 43 that is in interface contact with the hydrophilic solvent 42. The organic solvent 42 is lost from the droplet, or the 4MU concentration in the droplet is lowered.
  • the reaction between neuraminidase and 4MU-NANA is performed under pH conditions around 5 which is the optimum pH for the enzyme reaction by neuraminidase, and the detection of released 4MU is maximized with the fluorescence efficiency (quantum efficiency) of 4MU. It was carried out under a pH condition of around 10 which is a pH value.
  • one of the technical features of the present invention is that the reaction of neuraminidase with 4MU-NANA and the detection of 4MU are both carried out under pH conditions higher than 4MU pKa7.79. is there.
  • the reaction between the substrate 3 and the enzyme 5 can proceed if the substrate 3 and the enzyme 5 come into contact with each other even before this procedure.
  • the hydrophilic solvent 42 containing the virus 2 and the substrate 3 is used.
  • the generated reaction product 4 is not accumulated in the minimum volume. For this reason, in the optical detection of the reaction product 4, the influence of the reaction product 4 generated before the encapsulation procedure (2) is small enough to be ignored.
  • reaction product 4 from the droplets of the hydrophilic solvent 42 to the hydrophobic solvent 43 covering the droplets similarly
  • chromogenic substrates that can cause migration problems include:
  • Derivatives containing 4-methylumbelliferone other than 4MU-NANA are derivatives containing 4-methylumbelliferone other than 4MU-NANA.
  • the “derivative” means a compound having 4MU as “chromophore” and “substrate” cleaved by the reaction with the enzyme 5 in the structure.
  • resorufin as a chromophore.
  • the substrate When reacted with the enzyme 5, the substrate is cleaved by the enzyme 5 and resorufin (pKa: 6.0), which is a fluorescent substance, is released as the reaction product 4.
  • resorufin pKa: 6.0
  • the structure of resorufin is shown below.
  • the pH value of the hydrophilic solvent 42 is set larger than the acid dissociation constant (pKa) of the reaction product 4 generated from the derivative. Thereby, each reaction product 4 is brought into a charged state, is prevented from shifting (leaking out) to the hydrophobic solvent 43, and the reaction product 4 is accumulated in a high concentration in the droplets of the hydrophilic solvent 42. (See Example 1).
  • the concentration of the buffer substance is, for example, 50 mM or more, preferably 100 mM or more, more preferably 500 mM or more, and further preferably 1 M or more.
  • the optical detection of the reaction product 4 can be performed using a known means capable of detecting a difference in optical properties between the substrate 3 and the reaction product 4. For example, by detecting a specific absorbance or optical rotation shift using an image sensor, an absorptiometer, or a polarimeter, and by detecting a specific fluorescence wavelength using an image sensor, a fluorescence microscope, or a fluorometer. Product 4 can be detected optically.
  • the number of virus particles and / or subtypes can be determined.
  • influenza virus first, the enzyme activity value of neuraminidase is calculated using the detected fluorescence intensity and a standard curve that defines the relationship between the fluorescence intensity and neuraminidase activity prepared in advance. Next, the number of influenza virus particles is quantified using the calculated enzyme activity value and a standard curve that defines the relationship between the enzyme activity value and the number of virus particles prepared in advance. In addition to determining whether the biological sample separated from the subject contains viruses, the amount of virus can also be determined quantitatively (analog quantification), and whether or not the subject is infected with influenza virus. Can be diagnosed. A standard curve that directly defines the relationship between the fluorescence intensity and the number of virus particles may be used.
  • type A virus has higher neuraminidase activity than type B virus.
  • the inventors of the present invention use the detection method according to the present invention that the type A virus and the type B virus differ by about twice in neuraminidase activity, and that both can be effectively distinguished and detected based on the magnitude of the activity value. Heading.
  • the enzyme activity value of neuraminidase is calculated using the detected fluorescence intensity and a standard curve that defines the relationship between the fluorescence intensity and neuraminidase activity prepared in advance.
  • the subtype of influenza virus can be determined using the calculated enzyme activity value and the relational expression between the enzyme activity value and the subtype prepared in advance.
  • influenza virus it can be determined as type A if the calculated enzyme activity value is greater than or equal to the reference value, and can be determined as type B if it is less than the reference value.
  • the virus subtype in addition to the determination of whether the virus is contained in the biological sample separated from the subject, the virus subtype can also be determined, and the subtype of the infected influenza virus in the subject can be diagnosed.
  • a relational expression that directly defines the relationship between fluorescence intensity and subtype may be used.
  • the number of viruses 2 entering one container 13 can be 0 or 1 at the maximum.
  • the viral load can also be determined quantitatively (digital quantification) based on a defined standard curve.
  • the reaction product 4 can be accumulated in a high concentration in the droplets of the hydrophilic solvent 42, so that even when only one particle of virus 2 is contained in the container 13.
  • the reaction product 4 can be detected with high sensitivity. Therefore, according to the detection method of the present invention, even a very small amount of virus in a biological sample can be detected with high sensitivity, and the amount of pathogenic microorganisms can be determined with high accuracy.
  • reaction product 4 can be accumulated in a high concentration in the droplets of the hydrophilic solvent 42 to obtain a high fluorescence intensity
  • a simple imaging device with relatively low sensitivity can be used for optical detection.
  • optical detection with a camera mounted on a smartphone is expected to be possible.
  • Optical detection by a simple imaging device such as a camera mounted on a smartphone can facilitate the implementation of the pathogenic microorganism detection method according to the present invention in a relatively small hospital, clinic, or individual.
  • the communication means provided in the smartphone is used, the detection information of pathogenic microorganisms is transmitted to the server, and the accumulated information (big data) is analyzed, so that it is possible to grasp the epidemic area, time, subtype, etc. It is expected to be available for prediction.
  • the case where the virus 2 is an influenza virus and 4MU-NANA is used as the substrate 3 has been described as an example.
  • the substrate 3 includes hemagglutinin esterase (on the surface) of these viruses. What is necessary is just to use what hydrolyzes by the enzyme 5) and releases the chromophore (reaction product 4) as mentioned above.
  • the substrate 3 has reverse transcriptase (on the surface or inside thereof) It may be a nucleic acid monomer that is polymerized by the enzyme 5).
  • the fluorescence intensity increased as compared with the nucleic acid monomer is detected in the nucleic acid chain that is a reaction product of polymerization.
  • substrate 3 when the detection target is, for example, Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus or norovirus, substrate 3
  • a fluorescent dye can be prepared by labeling a fluorescent dye to a nucleic acid monomer that is polymerized by the RNA-dependent RNA polymerase (enzyme 5) possessed on the surface or inside of these viruses.
  • the substrate can be appropriately selected depending on the enzyme that is present on the surface or inside the pathogenic microorganism to be detected.
  • the pH value of the hydrophilic solvent used in the introduction procedure (1) may be designed to be larger than the pKa according to the pKa of the selected reaction product.
  • the substrate is a pathogenic microorganism having the same enzyme (neuraminidase) such as influenza virus and mump virus
  • the substrate can be designed differently depending on the substrate specificity of the enzyme of each pathogenic microorganism.
  • 4MU-NANA is used as a chromogenic substrate for detecting influenza virus
  • a chromophore produced by hydrolysis of 4MU-NANA as a chromogenic substrate for detecting mump virus is converted from 4MU to other fluorescent substances such as fluorescein. Use what was changed to.
  • the detection method according to the present invention can also detect both of them separately.
  • the method for detecting drug sensitivity of a pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with the pathogenic microorganism according to the present invention is as follows. including. (B1) A plurality of accommodating portions capable of accommodating pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface where the accommodating portion in the lower layer portion is formed. In the space between the upper layers facing each other, a hydrophilic solvent containing the biological sample, a substance serving as a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism, and an inhibitor of the enzyme Installation procedure to be introduced.
  • a hydrophobic solvent is introduced into the space, and droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substance, and the inhibitor are formed in the housing portion.
  • Enclosure procedure to. (B3) a detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet, wherein the detection intensity of the reaction product in the presence of the inhibitor is , If it is less than the detected intensity of the reaction product in the absence of the inhibitor, it indicates that the pathogenic microorganism is sensitive to the inhibitor).
  • the introduction procedure (B1) of the method for detecting drug susceptibility of pathogenic microorganisms according to the present invention is based on the above-described method for detecting pathogenic microorganisms only in that an enzyme inhibitor to be evaluated for drug sensitivity is contained in a hydrophilic solvent. Different from the introduction procedure (A1). In the introduction procedure (B1), in addition to the pathogenic microorganism and the substrate, an enzyme inhibitor present on the surface or inside of the pathogenic microorganism enters the container.
  • Encapsulation procedure (B2) The operation of the encapsulation procedure (B2) of the method for detecting drug sensitivity of a pathogenic microorganism according to the present invention is the same as the encapsulation procedure (A2) of the above-mentioned pathogenic microorganism detection method.
  • the encapsulation procedure (B2) droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substrate, and the inhibitor are formed in the container.
  • Detection Procedure (B3) In the detection procedure (B3) of the method for detecting drug susceptibility of pathogenic microorganisms according to the present invention, the reaction generated in the droplet of the hydrophilic solvent in the same manner as the detection procedure (A3) of the above-described pathogenic microorganism detection method. Optical detection of the product is performed.
  • the detection intensity of the reaction product in the presence of the inhibitor is compared with the detection intensity of the reaction product in the absence of the inhibitor, It is shown that the formation of reaction products in the droplets is suppressed. That is, the enzyme contained in the pathogenic microorganism is inhibited, which indicates that the pathogenic microorganism is sensitive to the inhibitor.
  • the detection intensity of the reaction product in the absence of the inhibitor is equivalent to the detection intensity of the reaction product in the absence of the inhibitor
  • the reaction in the droplet of the hydrophilic solvent Product formation is shown not to be inhibited by the inhibitor. That is, the enzyme contained in the pathogenic microorganism is not inhibited, indicating that the pathogenic microorganism is resistant to the inhibitor.
  • the pathogenic microorganism is an influenza virus, for example, using 4MU-NANA as a substrate and neuraminidase inhibitors (such as osetamivir, zanamivir) as inhibitors
  • neuraminidase inhibitors such as osetamivir, zanamivir
  • the generated 4MU fluorescence is detected for the two test groups that are identical except under the following conditions.
  • the detection intensity of 4MU in the presence of neuraminidase inhibitor is compared to the detection intensity of 4MU in the absence of neuraminidase inhibitor, if the former is reduced over the latter, the neuraminidase inhibitor will cause the It is shown that the generation of 4MU is suppressed.
  • influenza virus is sensitive to neuraminidase inhibitors.
  • the detection intensity of 4MU in the absence of neuraminidase inhibitor is comparable to the detection intensity of 4MU in the absence of neuraminidase inhibitor, the production of 4MU in the droplet of the hydrophilic solvent is neuraminidase. It is shown that it is not suppressed by the inhibitor. That is, the neuraminidase possessed by the influenza virus is not inhibited, indicating that the influenza virus is resistant to the neuraminidase inhibitor.
  • HE hemagglutinin esterase
  • HIV human immunodeficiency virus
  • hepatitis B virus or human T cell leukemia virus HTLV
  • inhibitors of reverse transcriptase retrovir ( GlaxoSmithKline Inc., Zidovudine / AZT), Videx (Bristol-Myers Squibb Inc., Zidanocin / ddI), Hibid (Hoffmanla Roche) (Zarcitabine / ddC), Zellit (Bristol-Myers Squibb), Stavudine / d4T), Epivir (GlaxoSmithKline, Lamivudine / 3TC) and Combivir (GlaxoSmithKline, Zidovudine / Lamivudine) Vilamune (Boehringer Ingelheim Pharmaceuticals Inc.
  • retrovir GlaxoSmithKline Inc., Zidovudine / AZT
  • Videx Bristol-Myers Squibb Inc., Zidanocin / d
  • RNA-dependent RNA polymerase Fabipyravir, ribavirin, etc.
  • Vibrio parahaemolyticus Vibrio parahaemolyticus, Campylobacter, Enterobacter or Bacillus spp. are targeted for detection, inhibitors of galactosidase (Castanospermine, Conduritol B Epoxide, Bromoconduritol, 2- etc.
  • Deoxy-D-Galactose Deoxy-D-Galactose
  • glucuronidase inhibitor Alsetoguraton, D-glucaro-1,4-lactone , lysophospholipids, etc.
  • chymotrypsin trypsin inhibitor
  • trypsin inhibitor Soybean, egg or the like derived trypsin inhibitor, Arg 4 - Examples include Met 5 -marinostatin, phenylmethylsulfonyl fluoride, aminoethyl benzylsulfonyl fluoride, Aprotinin, Tosyl lysine chloromethyl ketone, tosyl phenylalanine chloromethyl ketone, and inhibitors of xylosidase (Castanospermine, Xyl-amidine, etc.).
  • the inhibitor in the method for detecting drug susceptibility of pathogenic microorganisms according to the present invention, can be appropriately selected depending on the enzyme present on the surface or inside the pathogenic microorganism to be detected.
  • a method for screening an anti-pathogenic microbial drug according to the present invention includes the following procedures.
  • a hydrophilic solvent containing the pathogenic microorganism, a substance serving as a substrate for a reaction by an enzyme existing on or inside the pathogenic microorganism, and a candidate compound is introduced into a space between the upper layers facing each other. Installation procedure to do.
  • (C2) A hydrophobic solvent is introduced into the space, and droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substance, and the candidate compound are formed in the container. Enclosure procedure to. (C3) a detection procedure for optically detecting a reaction product generated by the reaction between the enzyme and the substance in the droplet, wherein the detection intensity of the reaction product in the presence of the candidate compound is , If it decreases below the detected intensity of the reaction product in the absence of the candidate compound, it indicates that the candidate compound has anti-pathogenic microbial activity).
  • the introduction procedure (C1) of the screening method for an anti-pathogenic microbial agent according to the present invention is the above-mentioned pathogenic microorganism only in that a candidate compound to be evaluated for anti-pathogenic microbial activity is contained in a hydrophilic solvent. This is different from the detection method introduction procedure (A1). In the introduction procedure (C1), in addition to the pathogenic microorganism and the substrate, the candidate compound enters the housing unit.
  • Encapsulation procedure (C2) The operation of the encapsulation procedure (C2) of the screening method for an anti-pathogenic microorganism according to the present invention is the same as the encapsulation procedure (A2) of the above-mentioned pathogenic microorganism detection method.
  • the encapsulation procedure (C2) droplets of a hydrophilic solvent that are coated with a hydrophobic solvent and include pathogenic microorganisms, substrates, and candidate compounds are formed in the container.
  • Detection Procedure (C3) In the detection procedure (C3) of the screening method for an anti-pathogenic microorganism according to the present invention, the reaction generated in the droplet of the hydrophilic solvent in the same manner as the detection procedure (A3) of the above-mentioned pathogenic microorganism detection method Optical detection of the product is performed.
  • the detection intensity of the reaction product in the presence of the candidate compound is compared with the detection intensity of the reaction product in the absence of the candidate compound. It is shown that the formation of reaction products in the droplets is suppressed. That is, the enzyme possessed by the pathogenic microorganism is inhibited, indicating that the candidate compound has anti-pathogenic microbial activity.
  • the detection intensity of the reaction product in the absence of the candidate compound is equivalent to the detection intensity of the reaction product in the absence of the candidate compound, the reaction in the droplet of the hydrophilic solvent Product formation is shown not to be inhibited by the inhibitor. That is, the enzyme possessed by the pathogenic microorganism is not inhibited, indicating that the candidate compound does not have anti-pathogenic microbial activity.
  • Pathogenic microorganism detection kit is a kit for detecting pathogenic microorganisms in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism, A space between a lower layer portion in which a plurality of accommodating portions capable of accommodating the pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed An array comprising an upper layer portion facing each other, and A substance that is a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism particles; A hydrophilic solvent having a pH value greater than the acid dissociation constant (pKa) of the reaction product produced by the reaction between the enzyme and the substance; A hydrophobic solvent.
  • pKa acid dissociation constant
  • the kit according to the present invention includes the above-described array 1, the substrate 3, the hydrophilic solvent 42, and the hydrophobic solvent 43. Since the substrate 3, the hydrophilic solvent 42, and the hydrophobic solvent 43 are as described above, the configuration of the array 1 will be described in more detail below.
  • the lower layer portion 10 of the array 1 includes a plate-like member 11 and a side wall 12 having a hydrophobic upper surface.
  • a plurality of accommodating portions 13 are formed separated from each other by the side walls 12.
  • the plate member 11 preferably has a hydrophilic surface. “Hydrophilic surface” refers to a surface that has a higher affinity with a hydrophilic solvent than with a hydrophobic solvent.
  • the plate-like member 11 may be a solid material, but for example, glass, silicon, polymer resin, or the like can be used.
  • the side wall 12 is a structure that separates each of the plurality of accommodating portions 13 provided on the surface of the plate-like member 11, preferably on the hydrophilic surface.
  • the side wall 12 has a hydrophobic upper surface. “Hydrophobic” is used herein in the same meaning as “lipophilic” and means that the affinity with a hydrophobic solvent is higher than the affinity with a hydrophilic solvent.
  • the side wall 12 only needs to have a hydrophobic upper surface, that is, a surface facing the upper layer portion 20, and the side surface, that is, the inner wall in the accommodating portion 13, may be hydrophobic or hydrophilic.
  • the side wall 12 may be composed of a hydrophilic structure and a hydrophobic layer formed on the upper surface thereof.
  • a hydrophilic structure for example, glass, silicon, polymer resin, or the like can be used.
  • a hydrophobic layer for example, a water-repellent resin, a fluorine-based polymer resin, or the like can be used.
  • the fluoropolymer resin include amorphous fluororesins. Amorphous fluororesin is preferably used because it has high hydrophobicity and low toxicity to biological samples.
  • amorphous fluororesin for example, at least one selected from CYTOP (registered trademark), TEFLON (registered trademark) AF2400, and TEFLON (registered trademark) AF1600 can be suitably used.
  • CYTOP registered trademark
  • TEFLON registered trademark
  • AF1600 TEFLON (registered trademark) AF1600
  • CYTOP registered trademark
  • TEFLON registered trademark
  • the side wall 12 may be made of a hydrophobic material.
  • a fluorine-based polymer resin for example, a paraxylylene-based polymer resin, or the like can be used.
  • the fluoropolymer resin include amorphous fluororesins.
  • the amorphous fluororesin the above-described resins can be suitably used.
  • the side wall 12 should just be comprised so that the some accommodating part 13 may be formed on the plate-shaped member 11, for example, is a plate-shaped structure by which the hole is formed in the position in which the accommodating part 13 is formed. There may be.
  • the housing portion 13 has a part of the surface of the plate-like member 11 as a bottom surface, and the bottom surface is hydrophilic.
  • the shape of the region surrounded by the bottom surface and the side surface of the accommodating portion 13 may be, for example, a cylindrical shape, a prismatic shape, or the like.
  • the bottom surface of the accommodating portion 13 is hydrophilic, and the top surface of the side wall 12 is hydrophobic.
  • the upper layer portion 20 for example, glass, silicon, polymer resin, or the like can be used.
  • the upper layer portion 20 faces the surface of the lower layer portion 10 on which the accommodating portion 13 is formed with a space 30 therebetween. That is, there is a space 30 between the side wall 12 and the hydrophobic layer 22. This space 30 constitutes a flow path. With this configuration, the array 1 has a flow cell structure.
  • the space 30 can be used between the lower layer portion 10 and the upper layer portion 20 as a flow path for flowing a fluid in a direction parallel to the surfaces where the lower layer portion 10 and the upper layer portion 20 face each other.
  • a through hole (not shown) for introducing a fluid into the space 30 may be formed in the lower layer portion 10 or the upper layer portion 20.
  • the lower layer part 10 may have a region where the accommodating part 13 is formed and a region where the accommodating part 13 is not formed.
  • the through-hole may be formed in the area
  • the surface of the upper layer portion 20 constituting the upper surface of the space 30 is hydrophobic
  • the lower surface of the space 30 is the hydrophobic upper surface of the side wall 12 and the accommodating portion 13. Therefore, all portions of the space 30 other than the bottom surface of the accommodating portion 13 are hydrophobic.
  • the hydrophilic solvent 42 can be efficiently introduced into each accommodating portion 13.
  • the hydrophobic solvent 43 is not allowed to enter the respective accommodating portions 13. Therefore, by introducing the hydrophobic solvent 43 into the space 30, it is possible to efficiently form droplets in the respective accommodating portions 13.
  • a positive type photoresist (AZ-4903, AZ Electronic Materials) was spin-coated on the cover glass coated with the amorphous fluororesin and baked at 55 ° C. for 3 minutes, and further baked at 110 ° C. for 5 minutes. Photolithography was performed using a photomask having holes having a diameter of 3 ⁇ m at intervals of 5 ⁇ m. After dry etching with oxygen plasma, a washed cover glass was obtained as DAD. The DAD has a well (accommodating portion) having a diameter of 4 ⁇ m and a depth of 3 ⁇ m (about 1 million pieces / 10 mm 2 ), and the cover glass is exposed on the bottom surface of the well. An array having a flow cell structure as shown in FIG. 1 was prepared using the obtained DAD.
  • 4-MU was dissolved in a buffer solution (33 mM DEA-HCl, 4 mM CaCl 2 ) adjusted to pH 6.5 to 9.0 to 50 ⁇ M.
  • 30 ⁇ L of a buffer solution in which 4-MU was dissolved was introduced into the array, and each well was filled with the buffer solution (see FIG. 1A).
  • 200 ⁇ L of a hydrophobic solvent (FC40) was introduced into the array, and droplets of the hydrophilic solvent coated with the hydrophobic solvent were formed in each well.
  • a fluorescence image of each droplet was taken with a CMOS camera (NeosCMOS, Andor) connected to a fluorescence microscope (IX8, OLYMPUS), and the fluorescence intensity was measured.
  • Photographing was performed by dividing an area of 10 mm 2 for each well into 120 parts. One image includes about 8,600 wells. The fluorescence image was analyzed with image analysis software (Meta-Morph, Molecular Devices), and the fluorescence intensity was calculated.
  • 4-MU was dissolved in a buffer solution (4 mM CaCl 2 , pH 6.5) adjusted to a DEA concentration of 25 mM to 1 M to a concentration of 50 ⁇ M.
  • 30 ⁇ L of a buffer solution in which 4-MU was dissolved was introduced into the array, and each well was filled with the buffer solution (see FIG. 1A).
  • 200 ⁇ L of a hydrophobic solvent (FC40) was introduced into the array, and droplets of the hydrophilic solvent coated with the hydrophobic solvent were formed in each well.
  • Time-lapse photography was performed under a fluorescence microscope, and the fluorescence intensity of each droplet was measured.
  • the fluorescence of 4MU can be detected with higher sensitivity by setting the concentration of the buffer substance in the buffer solution to 50 mM or more. Indicated. It is considered that the migration (leakage) of 4MU FC40 could be suppressed by setting the buffer substance in the buffer solution to a predetermined concentration or more.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Sustainable Development (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Optical Measuring Cells (AREA)

Abstract

L'invention concerne un procédé de détection de micro-organismes pathogènes dans un échantillon biologique, qui est une technique pouvant être utilisée pour effectuer une détection à haute sensibilité de micro-organismes pathogènes, tels que le virus de la grippe, etc., le procédé comprenant : une étape d'introduction pour introduire un solvant hydrophile qui contient l'échantillon biologique et des substances qui servent de substrats pour des réactions impliquant des enzymes qui sont présentes à la surface des micro-organismes pathogènes ou à l'intérieur de ces derniers dans un espace compris entre une section de couche inférieure dans laquelle une pluralité de sections de réception qui peuvent recevoir les micro-organismes pathogènes sont formées et une section de couche supérieure qui fait face à une surface dans laquelle les sections de réception sont formées dans la section de couche inférieure ; une étape d'encapsulation pour introduire un solvant hydrophobe dans l'espace et former, dans les sections de réception, des gouttelettes du solvant hydrophile qui sont revêtues par le solvant hydrophobe enveloppant les micro-organismes pathogènes et les substances ; et une étape de détection pour détecter optiquement des produits de réaction qui sont générés en résultat des réactions entre les enzymes et les substances présentes dans les gouttelettes, le solvant hydrophile ayant une valeur de pH qui est supérieure à la constante de dissociation acide (pKa) des produits de réaction.
PCT/JP2017/031689 2016-09-05 2017-09-04 Procédé et kit de détection de micro-organismes pathogènes WO2018043733A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/329,829 US11008603B2 (en) 2016-09-05 2017-09-04 Method and kit for detecting pathogenic microorganism
EP17846736.1A EP3508586A4 (fr) 2016-09-05 2017-09-04 Procédé et kit de détection de micro-organismes pathogènes
BR112019004272A BR112019004272A2 (pt) 2016-09-05 2017-09-04 método e kit para detectar micro-organismo patogênico
CN201780054148.5A CN109689882A (zh) 2016-09-05 2017-09-04 用于病原性微生物检测的方法及试剂盒

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2016-172515 2016-09-05
JP2016172515 2016-09-05
JP2017099579A JP7016136B2 (ja) 2016-09-05 2017-05-19 病原性微生物検出のための方法及びキット
JP2017-099579 2017-05-19

Publications (1)

Publication Number Publication Date
WO2018043733A1 true WO2018043733A1 (fr) 2018-03-08

Family

ID=61301218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/031689 WO2018043733A1 (fr) 2016-09-05 2017-09-04 Procédé et kit de détection de micro-organismes pathogènes

Country Status (2)

Country Link
JP (1) JP7274780B2 (fr)
WO (1) WO2018043733A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168200A1 (fr) * 2018-03-02 2019-09-06 国立研究開発法人科学技術振興機構 Procédé de détection d'un produit de réaction enzymatique
JPWO2020179858A1 (fr) * 2019-03-05 2020-09-10
US11008603B2 (en) 2016-09-05 2021-05-18 Japan Science And Technology Agency Method and kit for detecting pathogenic microorganism
CN113825830A (zh) * 2019-05-20 2021-12-21 日本航空电子工业株式会社 催化反应生成物的电化学检测方法和传感器
WO2022025044A1 (fr) * 2020-07-29 2022-02-03 京セラ株式会社 Dispositif de trajet d'écoulement

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60252464A (ja) * 1984-04-06 1985-12-13 クルト・ヴアレンフエルス ヒドロラ−ゼ用の基質およびそれらの製法
JP2002541858A (ja) 1999-04-16 2002-12-10 ザイメテックス インコーポレイテッド ウイルス由来の酵素および化学発光基質を用いるウイルス検出法
JP2003506455A (ja) * 1999-08-05 2003-02-18 スリーエム イノベイティブ プロパティズ カンパニー 発蛍光性化合物およびその使用
JP2006500940A (ja) * 2002-10-01 2006-01-12 メティス バイオテクノロジーズ 試料中の微生物を検出して、計数するための方法
JP2008275511A (ja) 2007-05-01 2008-11-13 Bl:Kk インフルエンザウイルス抗原の免疫測定法及びそれに用いられる物
JP2011139656A (ja) 2010-01-06 2011-07-21 Osaka Gas Co Ltd インフルエンザウイルスの検知方法およびインフルエンザウイルスの検知装置
JP2013101110A (ja) * 2011-10-21 2013-05-23 Hitachi High-Technologies Corp 液体クロマトグラフ及び分析法
JP2015034809A (ja) * 2013-07-10 2015-02-19 国立大学法人 東京大学 蛍光寿命イメージングプローブ
WO2016006208A1 (fr) * 2014-07-08 2016-01-14 国立研究開発法人科学技術振興機構 Procédé de scellement hermétique de substance et procédé de détection de molécule cible

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60252464A (ja) * 1984-04-06 1985-12-13 クルト・ヴアレンフエルス ヒドロラ−ゼ用の基質およびそれらの製法
JP2002541858A (ja) 1999-04-16 2002-12-10 ザイメテックス インコーポレイテッド ウイルス由来の酵素および化学発光基質を用いるウイルス検出法
JP2003506455A (ja) * 1999-08-05 2003-02-18 スリーエム イノベイティブ プロパティズ カンパニー 発蛍光性化合物およびその使用
JP2006500940A (ja) * 2002-10-01 2006-01-12 メティス バイオテクノロジーズ 試料中の微生物を検出して、計数するための方法
JP2008275511A (ja) 2007-05-01 2008-11-13 Bl:Kk インフルエンザウイルス抗原の免疫測定法及びそれに用いられる物
JP2011139656A (ja) 2010-01-06 2011-07-21 Osaka Gas Co Ltd インフルエンザウイルスの検知方法およびインフルエンザウイルスの検知装置
JP2013101110A (ja) * 2011-10-21 2013-05-23 Hitachi High-Technologies Corp 液体クロマトグラフ及び分析法
JP2015034809A (ja) * 2013-07-10 2015-02-19 国立大学法人 東京大学 蛍光寿命イメージングプローブ
WO2016006208A1 (fr) * 2014-07-08 2016-01-14 国立研究開発法人科学技術振興機構 Procédé de scellement hermétique de substance et procédé de détection de molécule cible

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Quantifying genetically inserted fluorescent protein in single iPS cells to monitor Nanog expression using electroactive microchamber arrays", LAB ON CHIP, vol. 14, no. 4, 2014, pages 730 - 736
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 9002-93-1
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 9005-64-5
KIM, S.H. ET AL.: "Quantifying genetically inserted fluorescent protein in single iPS cells to monitor Nanog expression using electroactive microchamber arrays", LAB ON A CHIP, vol. 14, 2014, pages 730 - 736, XP055579586 *
ROWLAND, B. ET AL.: "Fluorescence-based detection of lacZ reporter gene expression in intact and viable bacteria including Mycobacterium species", FEMS MICROBIOLOGY LETTERS, vol. 179, no. 2, 15 October 1999 (1999-10-15), pages 317 - 325, XP002320081, DOI: doi:10.1111/j.1574-6968.1999.tb08744.x *
S. SAKAKIHARA ET AL., LAB CHIP, vol. 10, 2010, pages 3355 - 3362
ZHANG, F. ET AL.: "A simple and rapid fluorescent meuraminidase enzymatic assay on a microfluidic chip", DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol. 74, no. 3, 2012, pages 263 - 266, XP028948608, DOI: doi:10.1016/j.diagmicrobio.2012.07.011 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008603B2 (en) 2016-09-05 2021-05-18 Japan Science And Technology Agency Method and kit for detecting pathogenic microorganism
WO2019168200A1 (fr) * 2018-03-02 2019-09-06 国立研究開発法人科学技術振興機構 Procédé de détection d'un produit de réaction enzymatique
JPWO2020179858A1 (fr) * 2019-03-05 2020-09-10
WO2020179858A1 (fr) * 2019-03-05 2020-09-10 国立研究開発法人科学技術振興機構 Procédé et kit de détection de virus de la grippe et procédé de diagnostic d'une infection par le virus de la grippe
EP3936618A4 (fr) * 2019-03-05 2023-01-25 Japan Science and Technology Agency Procédé et kit de détection de virus de la grippe et procédé de diagnostic d'une infection par le virus de la grippe
JP7454861B2 (ja) 2019-03-05 2024-03-25 国立研究開発法人科学技術振興機構 インフルエンザウイルス検出のための方法及びキット、並びにインフルエンザイウイルス感染の診断方法
CN113825830A (zh) * 2019-05-20 2021-12-21 日本航空电子工业株式会社 催化反应生成物的电化学检测方法和传感器
WO2022025044A1 (fr) * 2020-07-29 2022-02-03 京セラ株式会社 Dispositif de trajet d'écoulement
JP7483892B2 (ja) 2020-07-29 2024-05-15 京セラ株式会社 流路デバイス

Also Published As

Publication number Publication date
JP2022031760A (ja) 2022-02-22
JP7274780B2 (ja) 2023-05-17

Similar Documents

Publication Publication Date Title
JP7016136B2 (ja) 病原性微生物検出のための方法及びキット
JP7274780B2 (ja) 病原性微生物検出のための方法及びキット
JP6477940B2 (ja) 生体分子解析方法及び生体分子解析キット
AU2015286488B2 (en) Substance sealing method and target molecule detecting method
Obayashi et al. A single-molecule digital enzyme assay using alkaline phosphatase with a cumarin-based fluorogenic substrate
JP2023520754A (ja) ＳＡＲＳ－ＣｏＶ－２ウイルスの迅速で現場配備可能な検出
US11898194B2 (en) Method for detecting target molecule
Teixeira et al. An all-in-one point-of-care testing device for multiplexed detection of respiratory infections
US20120004141A1 (en) Amplified bioassay
Cló et al. Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis
WO2019168200A1 (fr) Procédé de détection d'un produit de réaction enzymatique
EP3974844A1 (fr) Procédé de détection de substance cible
JP4253695B2 (ja) 物質の定量方法及び物質の定量デバイス
Honda et al. Multidimensional digital bioassay platform based on an air-sealed femtoliter reactor array device
JP4519794B2 (ja) マイクロ流路素子
Cui et al. A facile and rapid route to self-digitization of samples into a high density microwell array for digital bioassays
Stromberg et al. Membrane insertion for the detection of lipopolysaccharides: Exploring the dynamics of amphiphile-in-lipid assays
US10018627B2 (en) Method for sealing substances, method for detecting target molecule, array, kit, and target molecule detection device
US20220088598A1 (en) Method of introducing liquid into wells
JP7454861B2 (ja) インフルエンザウイルス検出のための方法及びキット、並びにインフルエンザイウイルス感染の診断方法
Ortiz et al. Bleed‐to‐read disposable microsystems for the genetic and serological analysis of celiac disease markers with amperometric detection
Saito et al. Liposome Flotation Assay for Studying Interactions Between Rubella Virus Particles and Lipid Membranes
WO2000073800A1 (fr) Methode et trousse de dosage d'anticorps anti-gad

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17846736

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017846736

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019004272

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112019004272

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190301